Adaptive Biotechnologies (NASDAQ:ADPT) reported an insider sale by Chief Financial Officer Kyle Piskel, who sold 18,672 shares of the company’s common stock on March 11, 2026. The transaction was executed at $13.17 per share and produced gross proceeds of $245,910.
After the disposition, Piskel directly holds 259,840 shares of Adaptive Biotechnologies. Company disclosures state the sale was undertaken to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs). According to the company’s equity incentive plans, tax obligations tied to RSU vesting are required to be funded via a "sell to cover" transaction.
The share sale comes as ADPT shares have shown recent volatility. Over the prior week the stock fell 11%, even though it has gained 81% over the trailing 12 months. Market capitalization stands at $2.01 billion. InvestingPro analysis included in the company brief indicates the stock is trading above its Fair Value. Investors interested in more detailed analysis can access ADPT’s Pro Research Report, which is available alongside reports for more than 1,400 other U.S. equities.
In a separate disclosure of company results referenced in the filing, Adeptus Biotechnologies Corp reported fourth-quarter 2025 results that beat analyst expectations. The company delivered earnings per share of -$0.09, ahead of the -$0.18 forecast, and posted revenue of $71.7 million versus an anticipated $59.33 million, representing a 20.85% upside to consensus revenue estimates.
Following those fourth-quarter results, several analysts adjusted price targets while maintaining or reiterating coverage. TD Cowen increased its price target to $21 while keeping its prior stock rating unchanged. BTIG lifted its target to $22, citing strength in the company’s Minimal Residual Disease business, which expanded 54% year over year in the fourth quarter and grew 46% for the full year. Piper Sandler reiterated an Overweight rating and emphasized the company’s leading position in the minimal residual disease market, projecting more than 30% growth in clonoSEQ volumes.
These analyst moves and the reported operating metrics were highlighted as evidence of positive sentiment among coverage analysts and to underscore the firm’s recent operational momentum in its targeted business lines.
Summary of the transaction and related context:
- The CFO sale was a sell to cover tied to RSU tax withholding requirements under the company’s equity plans.
- ADPT’s share price has been volatile, with an 11% one-week decline and an 81% gain over the past year.
- Third-party analysis noted in the company brief indicates the stock is currently trading above its calculated Fair Value.